Finding better ways to deliver tuberculosis preventive therapy for people living with HIV.
Options for Delivery of Short-Course Tuberculosis Preventive Therapy: The 3HP Options Trial
This study is looking at how to make a new tuberculosis prevention treatment easier for people living with HIV in sub-Saharan Africa by comparing two ways of taking the medicine—one where a healthcare worker helps you take it, and another where you take it on your own—so that patients can have a say in what works best for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project ID | NIH-10784443 on NIH RePORTER |
What this research studies
This research investigates how to improve the delivery of a new tuberculosis preventive therapy called 3HP for people living with HIV in sub-Saharan Africa. The study aims to identify patient-centered strategies that enhance the uptake and completion of this therapy, which is crucial for reducing tuberculosis incidence. By comparing two delivery methods—directly observed therapy (DOT) and self-administered therapy (SAT)—the research focuses on shared decision-making to empower patients in their treatment choices. The goal is to make the therapy more accessible and acceptable to patients, ultimately improving health outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV in sub-Saharan Africa who are at risk of developing tuberculosis.
Not a fit: Patients who are not living with HIV or those who are not at risk for tuberculosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly increase the number of people living with HIV who complete tuberculosis preventive therapy, thereby reducing the incidence of tuberculosis in this vulnerable population.
How similar studies have performed: Previous research has shown that shorter, more patient-friendly regimens for tuberculosis prevention can improve adherence and outcomes, suggesting that this approach has potential for success.
Where this research is happening
Irvine, United States
- University of California-Irvine — Irvine, United States (Active)
Researchers
- Principal investigator: Cattamanchi, Adithya — University of California-Irvine
- Study coordinator: Cattamanchi, Adithya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.